Home
About
Disclaimer
Privacy

JCS/T2D - We are advocates. We learn. We share. We inform.

Enter Part of Title

Display #

Privacy

Articles

Join the 5K@ADA Virtual Challenge to Promote Diabetes Awareness and Healthy Living
Mounjaro: A New Player in the GLP-1 Arena for Type 2 Diabetes Management
Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss
Inequality in Clinical Trials for Diabetes Treatments: A Closer Look
Promising Phase 2 Results: Eli Lilly's Tirzepatide Shows Potential Beyond Diabetes and Obesity
Denmark's AI Supercomputer: A Leap Forward in Tackling Type 2 Diabetes and Obesity
How GLP-1 Receptor Agonists Can Help You Manage Type 2 Diabetes
Dexcom's Stelo: A New Era for Type 2 Diabetes Management
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
Innovative Weight Loss Medication Shows Promise in Lowering Blood Pressure
How Well Do My CGM and BGM Readings Match?
FDA Issues Warning on Non-Invasive Glucose Monitoring Devices
Understanding Obesity: Beyond the Scale
Diabetes and Eye Health
Novo Nordisk Announces Positive Results in Phase 3a Trial of IcoSema, a Combination of Semaglutide and Insulin Icodec for Type 2 Diabetes
The Dual Roles of GLP-1 and GLP-2 in Metabolic Health
Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
From Lab to Pharmacy: Navigating the Clinical Drug Trials and Approval Process in the US and EU
Exploring the Potential of Tirzepatide for Obstructive Sleep Apnea: A New Horizon in Treatment
Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living

News

October 2025

FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment

Contact Us

How many eyes does a typical person have?

Search

Search

You are here:
Home
JCS/T2D - A Diabetes Journey

Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.

Joomla! is Free Software released under the GNU General Public License.